SHR-A2102, a nectin-4 directed antibody-drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial.

In 30 seconds

This multicentre, single-arm phase 1 trial evaluated the safety and preliminary activity of SHR-A2102, a nectin-4 directed antibody-drug conjugate, in 395 patients with pretreated advanced solid tumours. The study found that 54% of patients experienced grade 3-4 treatment-related adverse events, with decreased neutrophil count being the most common. The maximum tolerated dose was not reached.

Key findings

• 54% of patients experienced grade 3-4 treatment-related adverse events.
• The most common adverse events included decreased neutrophil count (30%) and decreased white-blood-cell count (19%).
• One dose-limiting toxicity was reported at 10 mg/kg (grade 4 decreased platelet count).
• Treatment-related deaths occurred in two patients (<1%).

Why it matters

The findings suggest that SHR-A2102 may offer a new treatment option for patients with advanced solid tumours who have limited therapeutic alternatives. Understanding its safety profile and preliminary efficacy is crucial for future clinical applications.